NHNobuko Hamasaki-Katagiri

Nobuko Hamasaki-Katagiri

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Nobuko Hamasaki-Katagiri has a total of 75 co-authors. Here are the top co-authors by number of shared publications:

  • Chava Kimchi-Sarfaty

    Hemostasis Branch 1, Division of Hemostasis, Office of Plasma Protein Therapeutics, Office of Therapeutic Products, Center for Biologics Evaluation & Research, US Food and Drug Administration, Silver Spring, USA

    9 shared publications
  • Anton A. Komar

    Center for Gene Regulation in Health and Disease, Department of Biological, Geological and Environmental Sciences Cleveland State University Cleveland Ohio USA

    6 shared publications
  • Upendra Katneni

    Hemostasis Branch 1, Division of Hemostasis, Office of Plasma Protein Therapeutics, Office of Therapeutic Products, Center for Biologics Evaluation & Research, US Food and Drug Administration, Silver Spring, USA

    6 shared publications
  • David Holcomb

    Division of Hemostasis, Office of Therapeutic Products, Center for Biologics Evaluation and Research, US FDA , Silver Spring, MD, 20993

    5 shared publications
  • Aikaterini Alexaki

    Affiliation Center for Biologics Evaluation and Research, Office of Tissues and Advanced Therapies, Division of Plasma Protein Therapeutics, Food and Drug Administration, Silver Spring, Maryland, United States of America

    3 shared publications
  • Brian C. Lin

    Division of Hemostasis, Office of Therapeutic Products, Center for Biologics Evaluation & Research, US FDA

    3 shared publications

Latest Publications

  • Open Access

    Synonymous sequence design controls the folding, processing, and activity of the therapeutic protein ADAMTS13

    by Katarzyna I. Jankowska, Upendra K. Katneni, Brian C. Lin, Hannah M. Brenner, Randilu Amarasinghe, Nigam Padhiar, Patrick Dopler, Nobuko Hamasaki-Katagiri, Wells W. Wu, Haojie Zhu, et al.


  • Therapeutic implications of synonymous gene recoding: insights into mechanisms controlling protein biogenesis and activity

    by Brian C Lin, Katarzyna I Jankowska, Upendra K Katneni, Randilu Amarasinghe, Nigam Padhiar, Nobuko Hamasaki-Katagiri, Wells W Wu, Haojie Zhu, Hideki Taguchi, Arnab Ghosh, et al.


  • Open Access

    Synonymous ADAMTS13 variants impact molecular characteristics and contribute to variability in active protein abundance

    by Katarzyna Izabela Jankowska, Douglas Meyer, David Dillon Fisher Holcomb, Jacob Kames, Nobuko Hamasaki-Katagiri, Upendra K. Katneni, Ryan C. Hunt, Juan C. Ibla, Chava Kimchi-Sarfaty

    The effects of synonymous single nucleotide variants (sSNVs) are often neglected since they do not alter protein primary structure. Nevertheless, there is growing evidence that synonymous variations may impact mRNA expression, protein conformation and activity which may lead to protein deficiency and disease manifestations. As there are more than 21 million possible sSNVs affecting human genome, it is not feasible to experimentally validate the effect of each sSNV. Here, we report a comprehensive series of in-silico analyses assessing sSNV impact on a specific gene. A Disintegrin-like and Metalloprotease with Thrombospondin type-1 repeats, member-13 (ADAMTS13) was chosen as a model for its large size, many previously reported sSNVs and associated coagulopathy thrombotic thrombocytopenic purpura (TTP). Using various prediction tools of biomolecular characteristics, we evaluated all ADAMTS13 sSNVs registered in the NCBI dbSNP, including 357 neutral sSNVs and 19 sSNVs identified in TTP patients. We showed that some sSNVs change mRNA folding energy/stability, disrupt mRNA splicing, disturb micro RNAs (miRNAs) binding sites, and alter synonymous codon or codon pair usage. Our findings highlight the importance of considering sSNVs when assessing the complex effects of ADAMTS13 alleles and our approach provides a generalizable framework to characterize sSNV impact in other genes and diseases.


  • Open Access

    Structural, functional, and immunogenicity implications of F9 gene recoding

    by Upendra K. Katneni, Aikaterini Alexaki, Ryan C. Hunt, Nobuko Hamasaki-Katagiri, Gaya K. Hettiarachchi, Jacob M. Kames, Joseph R. McGill, David Dillon Fisher Holcomb, John C. Athey, Brian Lin, et al.

    Hemophilia B is a blood clotting disorder caused by deficient activity of coagulation factor IX (FIX). Multiple recombinant FIX proteins are currently approved to treat hemophilia B, and several gene therapy products are currently being developed. Codon optimization is a frequently used technique in the pharmaceutical industry to improve recombinant protein expression by recoding a coding sequence using multiple synonymous codon substitutions. The underlying assumption of this gene recoding is that synonymous substitutions do not alter protein characteristics because the primary sequence of the protein remains unchanged. However, a critical body of evidence shows that synonymous variants can affect cotranslational folding and protein function. Gene recoding could potentially alter the structure, function, and in vivo immunogenicity of recoded therapeutic proteins. Here, we evaluated multiple recoded variants of F9 designed to further explore the effects of codon usage bias on protein properties. The detailed evaluation of these constructs showed altered conformations, and assessment of translation kinetics by ribosome profiling revealed differences in local translation kinetics. Assessment of wild-type and recoded constructs using a major histocompatibility complex (MHC)-associated peptide proteomics assay showed distinct presentation of FIX-derived peptides bound to MHC class II molecules, suggesting that despite identical amino acid sequence, recoded proteins could exhibit different immunogenicity risks. Posttranslational modification analysis indicated that overexpression from gene recoding results in suboptimal posttranslational processing. Overall, our results highlight potential functional and immunogenicity concerns associated with gene-recoded F9 products. These findings have general applicability and implications for other gene-recoded recombinant proteins.


  • Open Access

    An Optimized Purification Design for Extracting Active ADAMTS13 from Conditioned Media

    by Katarzyna I. Jankowska, Upendra Katneni, Brian C. Lin, Randilu Amarasinghe, Je-Nie Phue, Wells W. Wu, Nobuko Hamasaki-Katagiri, Wojciech Jankowski, Rong-Fong Shen, Chava Kimchi-Sarfaty

    ADAMTS13 is a hemostatic enzyme that breaks down pro-thrombotic ultra-large multimers of von Willebrand factor (VWF). The deficiency of ADAMTS13 increases VWF-mediated thrombogenic potential and may lead to thrombotic thrombocytopenic purpura (TTP). Recently, clinical studies have shown the development of acquired TTP after COVID-19 infection and a correlation between low ADAMTS13 plasma levels and increased mortality. As a result, investigating ADAMTS13 as a potential recombinant therapeutic is of broad interest in the field of hematology. ADAMTS13 is considered challenging to purify in its biologically active state. Current purification methods utilize immobilized metal ions, which can interfere with ADAMTS13 metalloprotease activity. For this reason, we optimized an alternative strategy to isolate milligram quantities of highly active recombinant ADAMTS13 (rADAMTS13) from conditioned media after exogenous expression in human cell line, HEK293. HEK293 cells stably expressing C-terminal V5-His-tagged ADAMTS13 were grown in two parallel systems, culture bottles and flasks, for identifying an optimal cultivation strategy. Subsequently, we employed anion exchange followed by anti-V5-tag affinity chromatography to purify rADAMTS13, and extracted rADAMTS13 of high specific activity while preserving its native post-translational modifications. In addition, this process has been optimized and scaled up to produce active rADAMTS13 at levels sufficient for laboratory-scale structural, enzymatic, and biochemical studies.


  • Open Access

    Gene variants of coagulation related proteins that interact with SARS-CoV-2

    by David Holcomb, Aikaterini Alexaki, Nancy Hernandez, Ryan Hunt, Kyle Laurie, Jacob Kames, Nobuko Hamasaki-Katagiri, Anton A. Komar, Michael DiCuccio, Chava Kimchi-Sarfaty

    Thrombosis is a recognized complication of Coronavirus disease of 2019 (COVID-19) and is often associated with poor prognosis. There is a well-recognized link between coagulation and inflammation, however, the extent of thrombotic events associated with COVID-19 warrants further investigation. Poly(A) Binding Protein Cytoplasmic 4 (PABPC4), Serine/Cysteine Proteinase Inhibitor Clade G Member 1 (SERPING1) and Vitamin K epOxide Reductase Complex subunit 1 (VKORC1), which are all proteins linked to coagulation, have been shown to interact with SARS proteins. We computationally examined the interaction of these with SARS-CoV-2 proteins and, in the case of VKORC1, we describe its binding to ORF7a in detail. We examined the occurrence of variants of each of these proteins across populations and interrogated their potential contribution to COVID-19 severity. Potential mechanisms, by which some of these variants may contribute to disease, are proposed. Some of these variants are prevalent in minority groups that are disproportionally affected by severe COVID-19. Therefore, we are proposing that further investigation around these variants may lead to better understanding of disease pathogenesis in minority groups and more informed therapeutic approaches.


  • Open Access

    Potential impact on coagulopathy of gene variants of coagulation related proteins that interact with SARS-CoV-2

    by David Holcomb, Aikaterini Alexaki, Nancy Hernandez, Kyle Laurie, Jacob Kames, Nobuko Hamasaki-Katagiri, Anton A. Komar, Michael DiCuccio, Chava Kimchi-Sarfaty

    Thrombosis has been one of the complications of the Coronavirus disease of 2019 (COVID-19), often associated with poor prognosis. There is a well-recognized link between coagulation and inflammation, however, the extent of thrombotic events associated with COVID-19 warrants further investigation. Poly(A) Binding Protein Cytoplasmic 4 (PABPC4), Serine/Cysteine Proteinase Inhibitor Clade G Member 1 (SERPING1) and Vitamin K epOxide Reductase Complex subunit 1 (VKORC1), which are all proteins linked to coagulation, have been shown to interact with SARS proteins. We computationally examined the interaction of these with SARS-CoV-2 proteins and, in the case of VKORC1, we describe its binding to ORF7a in detail. We examined the occurrence of variants of each of these proteins across populations and interrogated their potential contribution to COVID-19 severity. Potential mechanisms by which some of these variants may contribute to disease are proposed. Some of these variants are prevalent in minority groups that are disproportionally affected by severe COVID-19. Therefore, we are proposing that further investigation around these variants may lead to better understanding of disease pathogenesis in minority groups and more informed therapeutic approaches. Author summary: Increased blood clotting, especially in the lungs, is a common complication of COVID-19. Infectious diseases cause inflammation which in turn can contribute to increased blood clotting. However, the extent of clot formation that is seen in the lungs of COVID-19 patients suggests that there may be a more direct link. We identified three human proteins that are involved indirectly in the blood clotting cascade and have been shown to interact with proteins of SARS virus, which is closely related to the novel coronavirus. We examined computationally the interaction of these human proteins with the viral proteins. We looked for genetic variants of these proteins and examined how these variants are distributed across populations. We investigated whether variants of these genes could impact severity of COVID-19. Further investigation around these variants may provide clues for the pathogenesis of COVID-19 particularly in minority groups.


  • Open Access

    Sequence analysis of SARS-CoV-2 genome reveals features important for vaccine design

    by Jacob Kames, David Dillon Holcomb, Ofer Kimchi, Michael DiCuccio, Nobuko Hamasaki-Katagiri, Tony Wang, Anton A. Komar, Aikaterini Alexaki, Chava Kimchi-Sarfaty

    As the SARS-CoV-2 pandemic is rapidly progressing, the need for the development of an effective vaccine is critical. A promising approach for vaccine development is to generate, through codon pair deoptimization, an attenuated virus. This approach carries the advantage that it only requires limited knowledge specific to the virus in question, other than its genome sequence. Therefore, it is well suited for emerging viruses for which we may not have extensive data. We performed comprehensive in silico analyses of several features of SARS-CoV-2 genomic sequence (e.g., codon usage, codon pair usage, dinucleotide/junction dinucleotide usage, RNA structure around the frameshift region) in comparison with other members of the coronaviridae family of viruses, the overall human genome, and the transcriptome of specific human tissues such as lung, which are primarily targeted by the virus. Our analysis identified the spike (S) and nucleocapsid (N) proteins as promising targets for deoptimization and suggests a roadmap for SARS-CoV-2 vaccine development, which can be generalizable to other viruses.


  • Open Access

    A Single Synonymous Variant (c.354G>A [p.P118P]) in ADAMTS13 Confers Enhanced Specific Activity

    by Ryan Hunt, Gaya Hettiarachchi, Upendra Katneni, Nancy Hernandez, David Holcomb, Jacob Kames, Redab Alnifaidy, Brian Lin, Nobuko Hamasaki-Katagiri, Aaron Wesley, et al.

    Synonymous variants within coding regions may influence protein expression and function. We have previously reported increased protein expression levels ex vivo (~120% in comparison to wild-type) from a synonymous polymorphism variant, c.354G>A [p.P118P], of the ADAMTS13 gene, encoding a plasma protease responsible for von Willebrand Factor (VWF) degradation. In the current study, we investigated the potential mechanism(s) behind the increased protein expression levels from this variant and its effect on ADAMTS13 physico-chemical properties. Cell-free assays showed enhanced translation of the c.354G>A variant and the analysis of codon usage characteristics suggested that introduction of the frequently used codon/codon pair(s) may have been potentially responsible for this effect. Limited proteolysis, however, showed no substantial influence of altered translation on protein conformation. Analysis of post-translational modifications also showed no notable differences but identified three previously unreported glycosylation markers. Despite these similarities, p.P118P variant unexpectedly showed higher specific activity. Structural analysis using modeled interactions indicated that subtle conformational changes arising from altered translation kinetics could affect interactions between an exosite of ADAMTS13 and VWF resulting in altered specific activity. This report highlights how a single synonymous nucleotide variation can impact cellular expression and specific activity in the absence of measurable impact on protein structure.